Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Rocket Pharmaceuticals, Inc.    RCKT

ROCKET PHARMACEUTICALS, INC.

(RCKT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapy treatment options for rare, devastating diseases. The Company’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The Company’s lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a genetic disease that leads to bone marrow failure and potentially cancer. Its additional pipeline programs for bone marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). The Company is also developing an AAV-based gene therapy program for pediatric heart failure indication, Danon disease.

Number of employees : 57 people.
Managers
NameAgeSinceTitle
Gaurav Shah, Dr.442018President, Chief Executive Officer & Director
Roderick T. Wong, Dr.422015Chairman
Kinnari Patel, Dr.40-Chief Operating Officer & EVP-Development
Jonathan David Schwartz, Dr.552018Chief Medical Officer & SVP-Clinical Development
Pedro P. Granadillo722018Independent Director
Gotham Makker, Dr.452018Independent Director
David P. Southwell582018Director
Carsten Boess522016Independent Director
Margareta Elisabeth Björk, Dr.582020Independent Director
John Militello452019Treasurer, Chief Accounting Officer & Controller
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 55,187,599 50,210,390 91.0% 0 0.0% 91.0%
Shareholders
NameEquities%
RTW Investments LP 16,812,491 30.5%
Tang Capital Management LLC 2,965,485 5.37%
Perceptive Advisors LLC 2,189,010 3.97%
Adage Capital Management LP 2,157,739 3.91%
The Vanguard Group, Inc. 1,824,334 3.31%
Westfield Capital Management Co. LP 1,711,501 3.10%
Wellington Management Co. LLP 1,688,990 3.06%
SSgA Funds Management, Inc. 1,588,389 2.88%
Eventide Asset Management LLC 1,550,000 2.81%
Cormorant Asset Management LP 1,468,550 2.66%
Company contact information
Rocket Pharmaceuticals, Inc.
The Empire State Building
350 5th Avenue
Suite 7530
New York, NY 10118

Phone : +1.646.440.9100
Fax : +1.646.224.9585
Web : http://www.rocketpharma.com
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
ROCKET PHARMACEUTICALS, INC.22.76%1 542
GILEAD SCIENCES, INC.-10.51%72 904
REGENERON PHARMACEUTICALS44.76%57 199
VERTEX PHARMACEUTICALS-4.84%54 210
WUXI APPTEC CO., LTD.71.31%40 863
BEIGENE, LTD.78.89%26 872
GENMAB A/S43.71%21 783
BIONTECH SE151.95%20 330
HUALAN BIOLOGICAL ENGINEERING INC.89.36%13 962
MYOKARDIA, INC.206.69%11 919
ARGENX SE49.30%11 829
SAREPTA THERAPEUTICS, INC.5.34%10 671
MIRATI THERAPEUTICS, INC.68.51%10 584
NEUROCRINE BIOSCIENCES, INC.-8.21%9 201
ASCENDIS PHARMA A/S17.42%8 691
ULTRAGENYX PHARMACEUTICAL INC.135.31%6 582
BIOCON LIMITED37.42%6 415
EXELIXIS, INC.16.23%6 328
ACCELERON PHARMA INC.97.25%6 264
ARROWHEAD PHARMACEUTICALS, INC.-9.66%5 861
PEPTIDREAM INC.-13.84%5 800